EN Official Journal of the European Union C 356/37

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2012

2014/C 356/08

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July-31 December 2012, at their meeting on 8 November 2013:

Annex I List of new marketing authorisations Annex II List of renewed marketing authorisations Annex III List of extended marketing authorisations Annex IV List of withdrawn marketing authorisations Annex V List of suspended marketing authorisations

ANNEX I List of new marketing authorisations The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July- 31 December 2012: EU-Number Product Country Date of authorisation EU/1/11/685/001-005 Ibandronic acid Sandoz Norway 31.7.2012 EU/1/11/719/001-062 Telmisartan Teva Pharma Liechtenstein 31.12.2012 EU/1/11/744/001-002 Topotecan Eagle Norway 30.8.2012 EU/1/11/747/001 Colobreathe Norway 11.7.2012 EU/1/11/748/001-006 Docetaxel Mylan Norway 17.12.2012 EU/1/12/762/001-018 Capecitabine Accord Norway 13.8.2012 EU/1/12/768/001 Riluzole Zentiva Norway 16.8.2012 EU/1/12/769/001-003 Docetaxel Accord Norway 13.8.2012 EU/1/12/771/001-006 Zoledronic Acid Teva Iceland 10.9.2012 EU/1/12/771/001-006 Zoledronic acid Teva Norway 12.10.2012 EU/1/12/772/001-004 Zoledronic acid Teva Pharma Iceland 10.9.2012 EU/1/12/772/001-004 Zoledronic acid Teva Pharma Norway 10.10.2012 EU/1/12/773/001-003 Jakavi Liechtenstein 31.8.2012 EU/1/12/773/001-003 Jakavi Norway 5.9.2012 EU/1/12/773/001-003 Jakavi Iceland 19.9.2012 EU/1/12/774/001-002 Rienso Norway 14.8.2012 EU/1/12/774/001-002 Rienso Iceland 20.7.2012 EU/1/12/774/001-002 Rienso Liechtenstein 31.12.2012 EU/1/12/775/001 NovoThirteen Iceland 17.9.2012 EU/1/12/775/001 Novo Thirteen Norway 19.9.2012 EU/1/12/775/001 Novo Thirteen Liechtenstein 31.10.2012 EU/1/12/776/001-016 Fycompa Norway 27.8.2012 EU/1/12/776/001-016 Fycompa Liechtenstein 31.8.2012 EU/1/12/776/001-016 Fycompa Iceland 11.9.2012 EU/1/12/777/001-006 Inlyta Iceland 14.9.2012 EU/1/12/777/001-006 Inlyta Norway 21.9.2012 EU/1/12/777/001-006 Inlyta Liechtenstein 31.10.2012 EU/1/12/778/001-003 Eklira Genuair Iceland 13.8.2012 EU/1/12/778/001-003 Eklira Genuair Norway 15.8.2012 EU/1/12/778/001-003 Eklira Genuair Liechtenstein 31.8.2012 EU/1/12/779/001-006 Zoledronic acid medac Norway 15.8.2012 EU/1/12/779/001-006 Zoledronic acid medac Iceland 27.8.2012 EU/1/12/779/001-006 Zoledronic acid medac Liechtenstein 31.8.2012 EU/1/12/780/001-028 Jentadueto Norway 31.7.2012 EU/1/12/780/001-028 Jentadueto Liechtenstein 31.8.2012 EU/1/12/780/001-028 Jentadueto Iceland 17.8.2012 EU/1/12/781/001-003 Bretaris Genuair Iceland 13.8.2012 EU/1/12/781/001-003 Bretaris Genuair Norway 15.8.2012 EU/1/12/781/001-003 Bretaris Genuair Liechtenstein 31.8.2012 EU/1/12/782/001-002 Kalydeco Norway 6.8.2012 EU/1/12/782/001-002 Kalydeco Iceland 21.8.2012 EU/1/12/782/001-002 Kalydeco Liechtenstein 31.8.2012 EU/1/12/783/001-003 Zyclara Liechtenstein 31.8.2012 EU/1/12/783/001-003 Zyclara Iceland 12.9.2012 EU/1/12/783/001-003 Zyclara Norway 10.10.2012 EU/1/12/784/001 Cuprymina Iceland 7.9.2012 EU/1/12/784/001 Cuprymina Norway 25.9.2012 EU/1/12/784/001 Cuprymina Liechtenstein 31.10.2012 EU/1/12/785/001 Zinforo Liechtenstein 31.8.2012 EU/1/12/785/001 Zinforo Iceland 6.9.2012 EU/1/12/785/001 Zinforo Norway 17.9.2012 EU/1/12/786/001-003 Zoledronic acid Mylan Liechtenstein 31.8.2012 EU/1/12/786/001-003 Zoledronic acid Mylan Iceland 4.9.2012 EU/1/12/786/001-003 Zoledronic acid Mylan Norway 12.10.2012 EU/1/12/787/001 Revestive Iceland 14.9.2012 EU/1/12/787/001 Revestive Norway 26.9.2012 EU/1/12/787/001 Revestive Liechtenstein 31.10.2012 EU/1/12/788/001-006 Seebri Breezhaler Iceland 16.10.2012 EU/1/12/788/001-006 Seebri Breezhaler Norway 17.10.2012 EU/1/12/789/001-006 Enurev Breezhaler Iceland 17.10.2012 EU/1/12/789/001-006 Enurev Breezhaler Norway 29.10.2012 EU/1/12/790/001-006 Tovanor Breezhaler Iceland 17.10.2012 EU/1/12/790/001-006 Tovanor Breezhaler Norway 29.10.2012 EU/1/12/791/001 Glybera Iceland 15.11.2012 EU/1/12/791/001 Glybera Norway 6.12.2012 EU/1/12/792/001 Dacogen Iceland 15.10.2012 EU/1/12/792/001 Dacogen Norway 17.10.2012 EU/1/12/792/001 Dacogen Liechtenstein 31.10.2012 EU/1/12/793/001-004 Xalkori Iceland 8.11.2012 EU/1/12/793/001-004 Xalkori Norway 14.11.2012 EU/1/12/793/001-004 Xalkori Liechtenstein 31.12.2012 EU/1/12/794/001 Adcetris Norway 10.12.2012 EU/1/12/794/001 Adectris Liechtenstein 31.12.2012 EU/1/12/795/001-010 Forxiga Norway 6.12.2012 EU/1/12/795/001-010 Forxiga Iceland 7.12.2012 EU/1/12/796/001-002 Picato Norway 27.11.2012 EU/1/12/796/001-002 Picato Iceland 7.12.2012 EU/1/12/796/001-002 Picato Liechtenstein 31.12.2012 EU/1/12/797/001-002 Eylea Norway 6.12.2012 EU/1/12/797/001-002 Eylea Iceland 13.12.2012 EU/1/12/798/001-004 Ibandronic acid Accord Norway 12.12.2012 EU/1/12/798/001-004 Ibandronic acid Accord Iceland 10.12.2012 EU/1/12/798/001-004 Ibandronic acid Accord Liechtenstein 31.12.2012 EU/1/12/799/001-029 Memantine Merz Iceland 12.12.2012 EU/1/12/799/001-029 Memantine Merz Liechtenstein 31.12.2012 EU/1/12/800/001-004 Zoledronic Acid Hospira Iceland 7.12.2012 EU/1/12/800/001-004 Zoledronic acid Hospira Norway 17.12.2012 EU/1/12/800/001-004 Zoledronic acid Hospira Liechtenstein 31.12.2012 EU/1/12/801/001-004 Constella Iceland 13.12.2012 EU/1/12/801/001-004 Constella Liechtenstein 31.12.2012 EU/1/12/801/001-004 Constella Norway 17.12.2012 EU/1/12/802/001-042 Capecitabine medac Norway 13.12.2012 EU/1/12/802/001-042 Capecitabine medac Iceland 18.12.2012 EU/1/12/802/001-042 Capecitabine medac Liechtenstein 31.12.2012 EU/2/09/099/001-006 Suvaxyn PCV Iceland 8.11.2012 EU/2/11/122/001-003 Bluevac BTV8 Norway 18.7.2012 EU/2/12/138/001-003 RevitaCAM Norway 19.9.2012 EU/2/12/140/001-008 Poulvac E. Coli Iceland 23.7.2012 EU/2/12/141/001-009 Porcilis ColiClos Iceland 5.7.2012 EU/2/12/141/001-009 Porcilis ColiClos Norway 31.7.2012 EU/2/12/141/001-009 Porcilis ColiClos Liechtenstein 31.8.2012 EU/2/12/142/001-006 Cardalis 2,5/20 mg Iceland 20.8.2012 EU/2/12/143/001-005 Nobivac L4 Iceland 20.8.2012 EU/2/12/143/001-005 Nobivac L4 Norway 28.8.2012 EU/2/12/143/001-005 Nobivac L4 Liechtenstein 31.8.2012

ANNEX II List of renewed marketing authorisations The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July- 31 December 2012: EU-Number Product Country Date of authorisation EU/1/01/187/001 DepoCyte Norway 13.8.2012 EU/1/01/197/001-005 Foscan Norway 7.9.2012 EU/1/02/222/001-005 Tamiflu Norway 21.8.2012 EU/1/02/223/001-003 Evra Iceland 5.7.2012 EU/1/02/223/001-003 Evra Norway 27.8.2012 EU/1/02/223/001-003 Evra Liechtenstein 31.8.2012 EU/1/02/224/001-005 Ambirix Iceland 21.8.2012 EU/1/02/224/001-005 Ambirix Norway 27.8.2012 EU/1/02/224/001-005 Ambirix Liechtenstein 31.8.2012 EU/1/02/226/001 InductOs Norway 2.8.2012 EU/1/02/226/001 InductOs Iceland 14.8.2012 EU/1/02/237/001-009 Cialis Norway 11.10.2012 EU/1/02/237/001-009 Cialis Iceland 17.10.2012 EU/1/02/237/001-009 Cialis Liechtenstein 31.10.2012 EU/1/02/238/001 Zavesca Iceland 22.10.2012 EU/1/02/238/001 Zavesca Norway 29.10.2012 EU/1/02/238/001 Zavesca Liechtenstein 31.10.2012 EU/1/05/314/001 Kepivance Norway 11.9.2012 EU/1/06/339/001-002 Preotact Norway 28.8.2012 EU/1/06/367/001-012 Diacomit Norway 12.12.2012 EU/1/06/367/001-012 Diacomit Iceland 13.12.2012 EU/1/06/367/001-012 Diacomit Liechtenstein 31.12.2012 EU/1/06/371/001-039 Dafiro Norway 26.9.2012 EU/1/06/376/001-039 Irbesartan Zentiva Iceland 28.9.2012 EU/1/07/393/001 Soliris Iceland 5.7.2012 EU/1/07/393/001 Soliris Norway 13.8.2012 EU/1/07/394/001-009 Optaflu Iceland 8.11.2012 EU/1/07/395/001-095 Invega Iceland 31.8.2012 EU/1/07/395/001-095 Invega Norway 11.9.2012 EU/1/07/397/001-004 Siklos Iceland 23.7.2012 EU/1/07/397/001-004 Siklos Norway 9.8.2012 EU/1/07/398/001-014 Optimark Iceland 5.7.2012 EU/1/07/398/001-014 Optimark Liechtenstein 31.8.2012 EU/1/07/401/007-016 alli Iceland 20.7.2012 EU/1/07/401/007-016 alli Liechtenstein 31.8.2012 EU/1/07/402/001 Increlex Iceland 29.8.2012 EU/1/07/402/001 Increlex Liechtenstein 31.8.2012 EU/1/07/402/001 Increlex Norway 3.9.2012 EU/1/07/403/001 Atriance Iceland 20.7.2012 EU/1/07/403/001 Atriance Norway 7.8.2012 EU/1/07/403/001 Atriance Liechtenstein 31.8.2012 EU/1/07/404/001-008 Flebogamma DIF Iceland 11.9.2012 EU/1/07/404/001-008 Flebogamma DIF Norway 12.10.2012 EU/1/07/405/001-040 Rasilez Liechtenstein 31.8.2012 EU/1/07/405/001-040 Rasilez Iceland 19.9.2012 EU/1/07/405/001-040 Rasilez Norway 10.10.2012 EU/1/07/409/001-040 Riprazo Iceland 12.9.2012 EU/1/07/409/001-040 Riprazo Norway 10.10.2012 EU/1/07/409/001-040 Riprazo Liechtenstein 31.8.2012 EU/1/07/410/001-052 Binocrit Norway 27.8.2012 EU/1/07/410/001-052 Binocrit Iceland 20.7.2012 EU/1/07/410/001-052 Binocrit Liechtenstein 31.8.2012 EU/1/07/411/001-052 Epoetin alfa Hexal Iceland 19.7.2012 EU/1/07/411/001-052 Epoetin alfa Hexal Norway 27.8.2012 EU/1/07/411/001-052 Epoetin alfa Hexal Liechtenstein 31.8.2012 EU/1/07/412/001-052 Abseamed Iceland 20.7.2012 EU/1/07/412/001-052 Abseamed Norway 27.8.2012 EU/1/07/413/001-003 Gliolan Iceland 7.9.2012 EU/1/07/413/001-003 Gliolan Norway 15.10.2012 EU/1/07/413/001-003 Gliolan Liechtenstein 31.10.2012 EU/1/07/414/001-010, 018 Galvus Iceland 17.8.2012 EU/1/07/414/001-010, 018 Galvus Norway 31.7.2012 EU/1/07/415/001-056 Zalasta Norway 24.8.2012 EU/1/07/415/001-056 Zalasta Iceland 25.8.2012 EU/1/07/415/001-056 Zalasta Liechtenstein 31.8.2012 EU/1/07/416/002 Ecalta Iceland 3.9.2012 EU/1/07/416/002 Ecalta Liechtenstein 31.8.2012 EU/1/07/416/002 Ecalta Norway 26.9.2012 EU/1/07/417/001-002 Yondelis Iceland 28.8.2012 EU/1/07/417/001-002 Yondelis Liechtenstein 31.8.2012 EU/1/07/417/001-002 Yondelis Norway 17.9.2012 EU/1/07/418/001-010 Celsentri Liechtenstein 31.8.2012 EU/1/07/418/001-010 Celsentri Iceland 12.9.2012 EU/1/07/418/001-010 Celsentri Norway 18.9.2012 EU/1/07/419/001-012 Cervarix Iceland 12.10.2012 EU/1/07/419/001-012 Cervarix Norway 12.10.2012 EU/1/07/419/001-012 Cervarix Liechtenstein 31.10.2012 EU/1/07/420/001-002 Cyanokit Iceland 14.8.2012 EU/1/07/420/001-002 Cyanokit Norway 17.8.2012 EU/1/07/420/001-002 Cyanokit Liechtenstein 31.8.2012 EU/1/07/421/001-009 Glubrava Iceland 12.10.2012 EU/1/07/421/001-009 Glubrava Norway 12.10.2012 EU/1/07/421/001-009 Glubrava Liechtenstein 31.10.2012 EU/1/07/422/001-012 Tasigna Norway 24.10.2012 EU/1/07/422/001-012 Tasigna Liechtenstein 31.10.2012 EU/1/07/422/001-012 Tasigna Iceland 6.12.2012 EU/1/07/424/001 Torisel Iceland 12.10.2012 EU/1/07/424/001 Torisel Norway 22.10.2012 EU/1/07/424/001 Torisel Liechtenstein 31.10.2012 EU/1/07/425/001-018 Eucreas Norway 31.7.2012 EU/1/07/425/001-018 Eucreas Iceland 21.8.2012 EU/1/07/425/001-018 Eucreas Liechtenstein 31.8.2012 EU/1/07/426/001-011 Olanzapine Neopharma Iceland 17.10.2012 EU/1/07/426/001-011 Olanzapine Neopharma Norway 24.10.2012 EU/1/07/426/001-011 Olanzapine Neopharma Liechtenstein 31.10.2012 EU/1/07/427/001-057 Olanzapine Teva Norway 6.12.2012 EU/1/07/427/001-057 Olanzapine Teva Iceland 7.12.2012 EU/1/07/427/001-057 Olanzapine Teva Liechtenstein 31.12.2012 EU/1/07/430/001-002 Atripla Norway 26.9.2012 EU/1/07/430/001-002 Atripla Iceland 12.10.2012 EU/1/07/431/001-025 Retacrit Iceland 7.12.2012 EU/1/07/431/001-025 Retacrit Norway 17.12.2012 EU/1/07/431/001-025 Retacrit Liechtenstein 31.12.2012 EU/1/07/432/001-022 Silapo Iceland 22.8.2012 EU/1/07/432/001-022 Silapo Norway 24.8.2012 EU/1/07/432/001-022 Silapo Liechtenstein 31.8.2012 EU/1/07/433/001 Nevanac Norway 15.10.2012 EU/1/07/433/001 Nevanac Liechtenstein 31.10.2012 EU/1/07/435/001-018 Tesavel Iceland 15.10.2012 EU/1/07/435/001-018 Tesavel Norway 15.10.2012 EU/1/07/437/001-004 IVEMEND Iceland 7.12.2012 EU/1/07/437/003-004 IVEMEND Norway 6.12.2012 EU/1/07/437/003-004 IVEMEND Liechtenstein 31.12.2012 EU/1/07/438/001-006 Myfenax Iceland 12.12.2012 EU/1/07/438/006 Myfenax Norway 13.12.2012 EU/1/07/439/001-006 Mycophenolate mofetil Teva Iceland 12.12.2012 EU/1/07/439/001-006 Mycophenolate mofetil Teva Norway 17.12.2012 EU/1/08/468/001-002 INTELENCE Iceland 16.8.2012 EU/1/08/468/001-002 INTELENCE Norway 27.8.2012 EU/1/08/468/001-002 INTELENCE Liechtenstein 31.8.2012 EU/1/11/710/001-007 Votubia Norway 16.8.2012 EU/1/11/710/001-007 Votubia Iceland 25.8.2012 EU/1/11/710/001-007 Votubia Liechtenstein 31.8.2012 EU/1/97/047/004-007 BeneFIX Iceland 16.8.2012 EU/1/97/047/004-007 BeneFIX Norway 24.8.2012 EU/1/97/047/004-007 BeneFIX Liechtenstein 31.8.2012 EU/2/02/032/001-002 Vaxxitek HVT + IBD Iceland 23.7.2012 EU/2/02/032/001-002 Vaxxitek HVT + IBD Liechtenstein 31.8.2012 EU/2/02/034/001 Nobivac Bb Iceland 18.9.2012 EU/2/02/034/001 Nobivac Bb Norway 23.10.2012 EU/2/02/034/001 Nobivac Bb Liechtenstein 31.10.2012 EU/2/07/072/001-004 Suprelorin Norway 31.7.2012 EU/2/07/072/001-004 Suprelorin Liechtenstein 31.8.2012 EU/2/07/074/001-006 Prilactone Liechtenstein 31.8.2012 EU/2/07/077/001-005 Meloxivet Iceland 6.12.2012 EU/2/07/077/001-005 Meloxivet Liechtenstein 31.10.2012

ANNEX III List of extended marketing authorisations The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July- 31 December 2012: EU-Number Product Country Date of authorisation EU/1/01/200/003-009 Viread Iceland 18.12.2012 EU/1/04/274/001-002 Velcade Norway 18.10.2012 EU/1/04/306/002-003 Aloxi Norway 19.11.2012 EU/1/06/368/169-174 Insulin Human Winthrop Liechtenstein 31.8.2012 EU/1/06/376/034, 036-039 Irbesartan Zentiva Liechtenstein 31.10.2012 EU/1/06/376/034, 036-039 Irbesartan Zentiva Norway 30.8.2012 EU/1/06/377/029-034 Irbesartan HCT Zentiva Liechtenstein 31.8.2012 EU/1/06/377/029-034 Irbesartan HCT Zentiva Norway 12.11.2012 EU/1/06/380/006 Prezista Iceland 14.11.2012 EU/1/06/380/006 Prezista Norway 24.10.2012 EU/1/07/389/004-009 Orencia Liechtenstein 31.10.2012 EU/1/07/389/004-009 Orencia Norway 13.11.2012 EU/1/07/389/004-009 Orencia Iceland 19.10.2012 EU/1/07/391/005-006 Revlimid Norway 25.9.2012 EU/1/07/391/005-006 Revlimid Iceland 11.10.2012 EU/1/07/440/007 Tyverb Liechtenstein 31.8.2012 EU/1/07/440/007 Tyverb Norway 31.7.2012 EU/1/09/514/021-023 Zebinix Liechtenstein 31.8.2012 EU/1/09/514/021-023 Zebinix Iceland 3.9.2012 EU/1/09/514/021-023 Zebinix Norway 25.9.2012 EU/1/10/616/025-036 Temozolomide HEXAL Liechtenstein 31.8.2012 EU/1/10/617/025-036 Temozolomide Sandoz Liechtenstein 31.8.2012 EU/1/11/691/006-013 Eliquis Iceland 11.12.2012 EU/1/11/691/006-013 Eliquis Norway 19.12.2012 EU/1/11/712/029-040 Levetiracetam Accord Liechtenstein 31.10.2012 EU/1/11/731/013-014 Komboglyze Liechtenstein 31.10.2012 EU/1/11/731/013-014 Komboglyze Norway 24.9.2012 EU/1/11/734/012-018 Edarbi Liechtenstein 31.8.2012 EU/1/11/735/012-018 Ipreziv Liechtenstein 31.8.2012 EU/1/12/752/002 Vepacel Liechtenstein 31.10.2012 EU/1/12/765/007-009 Sabervel Liechtenstein 31.12.2012 EU/1/97/030/196-201 Insuman Liechtenstein 31.8.2012 EU/1/97/047/008 BeneFIX Liechtenstein 31.8.2012 EU/1/97/047/008 BeneFIX Iceland 4.9.2012 EU/1/97/047/008 BeneFIX Norway 10.10.2012 EU/2/02/033/003-004 Dexdomitor Iceland 13.9.2012 EU/2/02/033/003-004 Dexdomitor Norway 30.8.2012 EU/2/02/033/003-004 Dexdomitor Liechtenstein 31.10.2012 EU/2/07/074/007-009 Prilactone Liechtenstein 31.12.2012 EU/2/07/078/018-020 Rheumocam Norway 6.12.2012 EU/2/07/078/018-020 Rheumocam Liechtenstein 31.12.2012 EU/2/08/090/028 Loxicom Liechtenstein 31.12.2012 EU/2/10/118/015-021 Activyl Liechtenstein 31.8.2012 EU/2/11/134/015-017 Inflacam Iceland 5.9.2012 EU/2/11/134/015-017 Inflacam Norway 1.11.2012 EU/2/11/134/015-017 Inflacam Liechtenstein 31.8.2012 EU/2/11/134/018-020 Inflacam Iceland 6.12.2012 EU/2/11/134/018-020 Inflacam Liechtenstein 31.12.2012 EU/2/99/015/003-004 Oxyglobin Liechtenstein 31.12.2012

ANNEX IV List of withdrawn marketing authorisations The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July- 31 December 2012: EU-Number Product Country Date of authorisation EU/1/00/147/001-012 Hexavac Iceland 23.7.2012 EU/1/00/147/001-012 Hexavac Liechtenstein 31.8.2012 EU/1/01/193/001-002 MabCampath Norway 8.8.2012 EU/1/01/193/001-002 MabCampath Iceland 30.8.2012 EU/1/01/193/001-002 MabCampath Liechtenstein 31.8.2012 EU/1/02/205/005-006 Lumigan Liechtenstein 31.12.2012 EU/1/02/209/001-004 Dynastat Norway 18.7.2012 EU/1/04/281/001-002, 004 Erbitux Norway 30.8.2012 EU/1/07/407/001-040 Sprimeo Iceland 23.7.2012 EU/1/07/407/001-040 Sprimeo Norway 4.7.2012 EU/1/07/407/001-040 Sprimeo Liechtenstein 31.8.2012 EU/1/09/513/001-020 Rivastigmine Teva Norway 10.9.2012 EU/1/09/513/001-020 Rivastigmine Teva Iceland 20.9.2012 EU/1/09/513/001-020 Rivastigmine Teva Liechtenstein 31.10.2012 EU/1/09/520/001-020 Exalief Iceland 6.12.2012 EU/1/09/520/001-020 Exalief Norway 30.7.2012 EU/1/09/570/001-060 Imprida HCT Iceland 7.12.2012 EU/1/09/576/040 Irbesartan Teva Liechtenstein 31.12.2012 EU/1/09/582/001 Rilonacept Regeneron Iceland 14.11.2012 EU/1/09/582/001 Rilonacept Regeneron Norway 24.10.2012 EU/1/10/634/005-011 Ribavirin Mylan Liechtenstein 31.12.2012 EU/1/11/638/001-080 Sprimeo HCT Liechtenstein 31.8.2012 EU/1/11/669/005 Teysuno Liechtenstein 31.12.2012 EU/1/11/679/007 Pravafenix Liechtenstein 31.12.2012 EU/1/11/680/001-080 Riprazo HCT Norway 30.8.2012 EU/1/11/680/001-080 Riprazo HCT Iceland 12.9.2012 EU/1/11/683/001-080 Sprimeo HCT Norway 6.7.2012 EU/1/11/683/001-080 Sprimeo HCT Iceland 23.7.2012 EU/1/11/691/006-013 Eliquis Liechtenstein 31.12.2012 EU/1/11/697/013-024 Temozolomide SUN Liechtenstein 31.12.2012 EU/1/12/765/007-009 Sabervel Liechtenstein 31.12.2012 EU/1/12/776/017-023 Fycompa Liechtenstein 31.12.2012 EU/1/12/780/029-034 Jentadueto Liechtenstein 31.12.2012 EU/1/96/006/008-011 NovoSeven Liechtenstein 31.12.2012 EU/1/97/040/001-002 Teslascan Iceland 14.9.2012 EU/1/99/099/001-006 Zerene Norway 23.8.2012 EU/1/99/099/001-006 Zerene Iceland 7.9.2012 EU/1/99/099/001-006 Zerene Liechtenstein 31.10.2012 EU/1/99/101/001 Regranex Norway 16.7.2012 EU/1/99/101/001 Regranex Liechtenstein 31.8.2012 EU/1/99/101/001 Regranex Iceland 14.8.2012 EU/1/99/103/009 Refacto AF Liechtenstein 31.12.2012